Developing new oral targeted therapies for RA can be challenging

Nature Reviews Rheumatology

Volumn 11, Issue 1, 2015, Pages 4-6

  Fleischmann, Roy M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOSTAMATINIB; METHOTREXATE; PLACEBO; ANTIRHEUMATIC AGENT;

DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; HYPERTENSION; MONOTHERAPY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SHORT SURVEY; ARTHRITIS, RHEUMATOID; MOLECULARLY TARGETED THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES; RADIOGRAPHY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84926408937     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2014.187     Document Type: Short Survey

References (10)

1. O'Shea, J. J., Laurence, A. & McInnes, I. B. Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat. Rev. Rheumatol. 9, 173-182 (2013).
2. Mócsai, A., Ruland, J. & Tybulewicz, V. L. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat. Rev. Immunol. 10, 387-402 (2010).
3. Weinblatt, M. E. et al. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheumatol. http://dx.doi.org/10.1002/art.3885.
4. Genovese, M. C. et al. A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist. J. Rheumatol. http://dx.doi.org/10.3899/jrheum.140238 (2014).
5. Weinblatt, M. E. et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 58, 3309-3318 (2008).
6. Weinblatt, M. E. et al. Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, doubleblind, placebo-controlled trial. J. Rheumatol. 40, 369-378 (2013).
7. Fleischmann, R. et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 367, 495-507 (2012).
8. Van Vollenhoven, R. et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367, 508-519 (2012).
9. Burmester, G. R. et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381, 451-460 (2013).
10. Genovese, M. C. et al. 24-week results of a blinded phase 2b dose-ranging study of baricitinib, an oral Janus kinase 1/Januse kinase 2 inhibitor, in combination with traditional disease modifying antirheumatic drugs in patients with rheumatoid arthritis [abstract 2487]. Arthritis Rheum. 64 (Suppl.), S1049-S1050 (2012).